Opinion: dealing with failure, iTeos style
When your investment case breaks down, why not just do the decent thing?
DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
EHA 2025 – ELVN-001 enlivens investors
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
EHA 2025 – Incyte puts its foot on the CALR gas
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
Backed by ASCO data Arcus guns for phase 3
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
AbbVie's telisotuzumab conjugate take two
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
